LOWER DRUG COSTS NOW ACT

Amendments

Enact (H.R. 3), H10167, H10202, H10204, H10205, H10207, H10208, H10210, H10211, H10214, H10215, H10216, H10217 [12DE]

——— consideration (H. Res. 758), H10041 [11DE]

Analyses

Provisions (H.R. 3), E1572 [10DE]

Articles and editorials

Price Controls Would Stifle Biotech Innovation, H10132 [12DE]

Bills and resolutions

Enact (see H.R. 3), H7834 [19SE]

Enact (H.R. 3): consideration (see H. Res. 758), H10015 [10DE]

Letters

Provisions: Sara Stewart, H10109 [11DE]

——— several biotechnology organizations, H10097 [11DE]

——— several pharmaceutical companies, H10130 [12DE]

Lists

Availability of medications in H.R. 3, provisions, reference countries, H10099–H10101 [11DE]

Top Medicare Part B drugs not covered by Dept. of Veterans Affairs (excluding vaccines), H10099 [11DE], H10217 [12DE]

Motions

Enact (H.R. 3), H10223 [12DE]

——— consideration (H. Res. 758), H10044 [11DE]

Remarks in House

Dept. of HHS: add a new set of measures to Medicare Advantage program 5-star rating system in order to encourage increased access to biosimilar biological products, H10203, H10204 [12DE]

——— address opioid drug abuse epidemic, H10032 [11DE]

——— allow Dept. of Veterans Affairs to purchase drugs at Fair Price Negotiation Program prices, H10216, H10217 [12DE]

——— authorize a pilot program to develop, expand, and enhance commercialization of biomedical products, H10204, H10205 [12DE]

——— create grant program for hospitals located in rural and medically underserved areas, including Critical Access Hospitals, to cover start-up costs for establishing a graduate medical education (GME) program, H10207, H10208 [12DE]

——— ensure Fair Price Negotiation Program and Medicare changes to reduce drug prices will not result in fewer new drug applications for unmet medical needs and life-saving cures, H10223, H10224 [12DE]

——— establish graduate medical education grant program for hospitals in rural and medically underserved areas, H9157 [21NO]

——— establish grant program for States to reduce unnecessary costs and administrative burdens in health care, H10213, H10214 [12DE]

——— include coverage for Federal employee health plans in Fair Price Negotiation Program to reduce drug prices, H10215, H10216 [12DE]

——— prevent spread pricing in Medicaid by pharmacy benefit managers and increase funding for NIH clinical trials, H10218 [12DE]

——— require another Senate-confirmed officer within the Dept., to carry out drug price negotiation duties should the Sec. of HHS have a conflict of interest, H10205, H10206 [12DE]

Drugs: acknowledge impact of high cost of prescription drugs on communities of color and persons living in rural or sparsely populated areas, H10208–H10210 [12DE]

——— lower out of pocket spending, protect access to new cures and medications, strengthen transparency, and encourage competition, H10133–H10139, H10201, H10202, H10204, H10209, H10211, H10215, H10216, H10219, H10235 [12DE]

——— require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising, H10214, H10215 [12DE]

Enact (H.R. 3), H7854–H7857 [20SE], H7873 [24SE], H7996 [26SE], H8153 [16OC], H8207 [17OC], H8232, H8250, H8252 [18OC], H8371, H8374 [22OC], H8397, H8398 [23OC], H8592 [29OC], H8606, H8607, H8608 [30OC], H8682 [31OC], H8775 [12NO], H8792 [13NO], H8831, H8835, H8873 [14NO], H8884, H8905, H8906 [15NO], H8963, H8966, H9052–H9054 [19NO], H9157 [21NO], H9210 [3DE], H9288–H9290 [5DE], H9955, H9956 [10DE], H10020, H10022, H10023, H10025, H10026, H10027, H10031, H10032, H10033, H10096–H10122 [11DE], H10128, H10129–H10225, H10235 [12DE]

——— consideration (H. Res. 758), H10033–H10042 [11DE]

——— motion to recommit, H10223, H10224 [12DE]

FDA: invest in qualified clinical testing for high-risk, high-reward drugs that address unmet medical needs to treat rare and life-threatening diseases, H10210, H10211 [12DE]

Medicare: provide coverage for certain vision items and services under part B, H10136 [12DE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D, H10038 [11DE]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D, H10135 [12DE]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans, H10110 [11DE]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation, H10134 [12DE]

Remarks in Senate

Enact (H.R. 3), S5587 [19SE], S5619 [23SE], S5636 [24SE], S5716 [26SE], S5934 [22OC], S6205 [29OC], S6271 [30OC], S6523 [13NO], S6958 [11DE], S7037 [16DE]

Reports filed

Consideration of H.R. 3, Provisions: Committee on Rules (House) (H. Res. 758) (H. Rept. 116–334), H10015 [10DE]

Provisions: Committee on Education and Labor (House) (H.R. 3) (H. Rept. 116–324), H9386 [9DE]

——— Committee on Energy and Commerce (House) (H.R. 3) (H. Rept. 116–324), H9345 [6DE]

——— Committee on Ways and Means (House) (H.R. 3) (H. Rept. 116–324), H9345 [6DE]

Statements

Provisions: Executive Office of the President, H10098 [11DE]

Texts of

H. Res. 758, consideration of H.R. 3, provisions, H10033 [11DE]

H.R. 3, provisions, H10141–H10167 [12DE]